Fundraising Fox

Ascendis Pharma

also invests · investor profile

Denmark, DK · Founded 2007 · 1,437 employees on LinkedIn · 6 known investors

Find your way into Ascendis Pharma

1,159 people in our graph share verified history with the Ascendis Pharma team — schools, employers, funds. One of them is your warm intro.

Jen Wangunlockedknows Martin Auster · together at UBS (overlapped)
×3knows the team · via Morgan Stanley
×6knows the team · via Credit Suisse
knows the team · via UBS
knows the team · via Novo Nordisk

Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.

BiotechHealthtechMedical Devices

Founders & leadership

Ascendis Pharma was founded in 2007 by Jan Møller Mikkelsen.

JMJan Møller Mikkelsen
Jan Møller MikkelseninFounder, President and Chief Executive OfficerJan Møller Mikkelsen founded Ascendis Pharma in 2007 and serves as President and CEO. The company develops long-acting therapeutic formulations using its TransCon technology platform for endocrinology, rare disease, and oncology indications.
GR
Grethe RasmusseninExecutive
HR
Harald RauExecutive
MO
Martin OlinExecutive
LS
Lotte S?nderbjergExecutive
MAMartin Auster
Martin AusterinExecutiveMartin Auster is an equity research analyst with a medical background and experience in both sell-side research and hedge fund investing. He has held positions in biotech corporate development, including work on fundraising, strategy, and business development, and previously led small-cap biotechnology research at Credit Suisse.
MW
Michael Wolff JenseninChairman Of The Board Of Directors2008–2021Michael Wolff Jensen is Executive Officer and Director at Ascendis Pharma, a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. He brings over 25 years of experience in pharmaceutical and life sciences, including executive leadership roles in legal, corporate affairs, and governance, as well as prior experience in CFO and strategic partnership functions.

Board

JH
James HealyBoard director
RT
Rafa?le TordjmanBoard director
JS
Jonathan SilversteinBoard director
MM
Michael MayerBoard director
ED
Edwin de GraafBoard director

Investors · 6

Vivo Capital✓ verifiedPalo Alto · $10M – $50M
Aisling CapitalNew York
Avoro Capital AdvisorsNew York
Foresite CapitalWest Hollywood
RA CapitalBoston
Sofinnova VenturesMenlo Park · $100K – $15M

Reported raises · per SEC filings

Form D private placements

$60M disclosed across 1 round · 2014

▶$60MraisedDec 2014 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • James HealyDirector
  • Grethe RasmussenExecutive Officer
  • Harald RauExecutive Officer
  • Rafa?le TordjmanDirector
  • Martin OlinDirector
  • Jan M?ller MikkelsenExecutive Officer, Director
  • Lotte S?nderbjergExecutive Officer
  • Martin AusterExecutive Officer
  • Jonathan SilversteinDirector
  • Michael Wolff JensenExecutive Officer, Director
  • Michael MayerDirector
  • Edwin de GraafDirector
  • Thomas SolowayExecutive Officer
  • Albert ChaDirector
Offering amount
$60M
Amount sold
$60M
First sale
Nov 2014
Incorporated
Other, Denmark
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape41 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Ascendis Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Dorsey Wright & Associates Acquires 3,375 Shares of Ascendis Pharma A/S $ASND - Daily Politicaldailypolitical.com · Jul 2026BofA raises Ascendis Pharma stock price target on revenue outlook By Investing.cominvesting.com · Jul 2026Ascendis Pharma (ASND) Stock Looks Above Fair Value As Shares Jump 24%finance.yahoo.com · Jul 2026Ascendis Pharma Closes Warrant Exercise Window, Expands Share Capital - TipRanks.comtipranks.com · Jun 2026Ascendis Pharma details warrant exercises, capital boost | ASND SEC Filing - Form 6-Kstocktitan.net · Jun 2026Ascendis Pharma jumps as investors weigh cash boost, pipeline momentum, and possible index-related buying | Quiver Quantitativequiverquant.com · Jun 2026

Frequently asked questions

What does Ascendis Pharma do?
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases. The company focuses on long-acting therapeutic formulations to address endocrine and rare disease indications.
Who founded Ascendis Pharma?
Ascendis Pharma was founded by Jan Møller Mikkelsen in 2007.
Who are Ascendis Pharma's investors?
Ascendis Pharma's investors include Vivo Capital, Aisling Capital, Avoro Capital Advisors, Foresite Capital, RA Capital, Sofinnova Ventures.
How much funding has Ascendis Pharma raised?
Ascendis Pharma has disclosed $60M raised across 1 round.
Where is Ascendis Pharma headquartered?
Ascendis Pharma is headquartered in Denmark, DK.